Eton Pharmaceuticals, Inc. (ETON) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

22/25

Growth 5 Margin 5 Expansion 5 Platform 2 Financial 5

latest quarter score

Earnings Reports

22
Eton Pharmaceuticals (ETON) Q2 2026: 99% Revenue Surge Driven by Hemangiol Relaunch and ASN-001 Acquisition
August 18, 2026
22
Eton Pharmaceuticals (ETON) Q1 2026: Guidance Raised 9% as Hemangiol Launch Bolsters Rare Disease Runway
May 15, 2026
21
Eton Pharmaceuticals (ETON) Q4 2025: EBITDA Margin Jumps to 29% as Rare Disease Portfolio Expands
March 20, 2026
19
Eton Pharmaceuticals (ETON) Q3 2025: Margin Set to Jump 25 Points as Product Mix Shifts
November 07, 2025
22
ETON (ETON) Q2 2025: Increlex Patient Base Surges 49%, Accelerating Revenue Run Rate Timeline
August 08, 2025
22
ETON Q1 2025: Product Sales Jump 76% as Rare Disease Pipeline Accelerates
July 06, 2025
19
Eton Pharmaceuticals (ETON) Q4 2024: Increlex Relaunch Drives 59% Revenue Surge, Poised for $100M Near-Term Growth
March 18, 2025

Browse all companies